Table 1.
Completed clinical trials of chemotherapy combined with immune checkpoint inhibitor therapy.
| Clinical Trials | Cancer types | Intervention | ORR(%) | OS(%) | PFS(%) |
|---|---|---|---|---|---|
| KEYNOTE826(III) [132] | Cervical Cancer | (1) pembrolizumab＋chemotherapy (2) placebo ＋chemotherapy |
– | 53.0 41.7 |
10.4 8.1 |
| NCT03257267(III) [133] | Cervical Cancer | (1) cemiplimab (2) single-agent chemotherapy |
– | 12.0 8.5 |
2.8 2.9 |
| NCT02580058(III) [134] | Ovarian Cancer | (1) avelumab (2) avelumab + PLD (3) PLD |
– | 18.2 18.4 17.4 |
1.9 3.7 3.5 |
| NCT03038100(III) [135] | Ovarian Cancer | (1) atezolizumab + PC + bevacizumab (2) placebo + PC + bevacizumab |
– | 19.5 18.4 |
|
| NCT02718417(III) [136] | Ovarian Cancer | (1) PC (2) PC + avelumab |
terminate | ||
| NCT02901899(II) [137] | Ovarian Cancer | (1) pembrolizumab + gemcitabine | 27.0 | – | |
| NCT02853318(II) [138] | Ovarian Cancer | (1) pembrolizumab + bevacizumab + cyclophosphamide | 47.5 | – | 10 |
| NCT02900560(II) | Ovarian Cancer | (1) pembrolizumab + azacytidine (2) pembrolizumab |
– | ||
| NCT03899610(II) [139] | Ovarian Cancer | (1) durvalumab + tremelimumab + chemotherapy | 100 | – | |